Who’s the Boss? Companies and Their Novel Drug Approvals, 2014-2018
Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs that has a troubling history of adverse events. The SOLAR-1 trial studied BYL719 in combination with fulvestrant compared to fulvestrant alone in postmenopausal women and … Συνεχίστε να διαβάζετε Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling History.